Rabbit ADAR1 Polyclonal Antibody | anti-ADAR1 antibody

ADAR1 Antibody

Cat. Num. AAA9505122

• Gene Names: ADAR; DSH; AGS6; G1P1; IFI4; P136; ADAR1; DRADA; DSRAD; IFI-4; K88DSRBP
• Reactivity: Human, Mouse, Rat
• Applications: Immunohistochemistry, ELISA
• Purity: Purified from rabbit antiserum by affinity-chromatography using immunogen.
• Synonyms: ADAR1; Polyclonal Antibody; ADAR1 Antibody; 136 kDa double-stranded RNA binding protein; DRADA; DSH; DSRAD; IFI-4 protein; IFI4; P136; double-stranded RNA-specific adenosine deaminase; interferon-inducible protein 4; anti-ADAR1 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Specificity: ADAR1 Antibody detects endogenous levels of total ADAR1 protein.
• Purity/Purification: Purified from rabbit antiserum by affinity-chromatography using immunogen.
• Form/Format: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: 1 mg/ml (varies by lot)
• Sequence Length: 931

• Applicable Applications for anti-ADAR1 antibody: Immunohistochemistry (IHC), ELISA (EIA)
• Application Notes: IHC: 1:50~1:100; ELISA: 1:20000
• Target Modification: Unmodified/Total
• Immunogen: The antiserum was produced against synthesized peptide derived from human ADAR1.
• Immunogen Range: 1172-1221
• Preparation and Storage: Stable at -20 degree C for at least 1 year.

Immunohistochemistry (IHC)

(Immunohistochemistry analysis of paraffin-embedded human brain tissue, using ADAR1 Antibody. The picture on the right is blocked with the synthesized peptide.)

NCBI and Uniprot Product Information

• NCBI GI #: 70167113
• NCBI GeneID: 103
• NCBI Accession #: NP_001020278.1
• NCBI GenBank Nucleotide #: NM_001025107.2
• UniProt Accession #: P55265; O15223; O43859; O43860; Q9BYM3; Q9BYM4; B1AQQ9; B1AQR0; D3DV76
• Molecular Weight: 135 kDa
• NCBI Official Full Name: double-stranded RNA-specific adenosine deaminase isoform d
• NCBI Official Synonym Full Names: adenosine deaminase, RNA specific
• NCBI Official Symbol: ADAR
• NCBI Official Synonym Symbols: DSH; AGS6; G1P1; IFI4; P136; ADAR1; DRADA; DSRAD; IFI-4; K88DSRBP
• NCBI Protein Information: double-stranded RNA-specific adenosine deaminase
• UniProt Protein Name: Double-stranded RNA-specific adenosine deaminase
• UniProt Gene Name: ADAR
• UniProt Synonym Gene Names: ADAR1; DSRAD; G1P1; IFI4; p136; IFI-4

NCBI Description

This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2010]

Uniprot Description

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.